Variation in policies for the management of febrile neutropenia in United Kingdom Children's Cancer Study Group centres
- PMID: 17284481
- PMCID: PMC2066132
- DOI: 10.1136/adc.2006.102699
Variation in policies for the management of febrile neutropenia in United Kingdom Children's Cancer Study Group centres
Abstract
Objective: To assess the variation in the current UK management strategies for the treatment of febrile neutropenia in childhood.
Design and setting: A postal survey of all 21 United Kingdom Children's Cancer Study Group (UKCCSG) centres assessing and collating local policies, protocols or guidelines relating to the management of febrile neutropenia. Further direct contact was undertaken to clarify any uncertainties.
Results: All 21 centres provided information. The policies used to manage febrile neutropenia in the centres around the UK vary in almost every aspect of management. Definitions of fever ranged from a persistent temperature of >37.5 degrees C to a single reading of >39 degrees C. Neutropenia was inconsistently defined as an absolute neutrophil count of <1x10(9), <0.75x10(9 )or <0.5x10(9). Choices of antibiotic approaches, empirical modifications and antistaphylococcal treatment were different in each protocol. The use of risk stratification was undertaken in 11 centres, with six using a policy of reduced intensity therapy in low risk cases. Empirical antifungal treatment was very poorly described and varied even more widely.
Conclusions: There was a great deal of variation in definitions and treatment of febrile neutropenia in the UKCCSG children's cancer treatment centres. A degree of variation as a result of local microbiological differences is to be expected, but beyond this we should seek to standardise the core of our approach to defining fever and neutropenia, risk stratification and duration of empirical therapy in a way that maintains safety, minimises resource utilisation and maximises quality of life.
Conflict of interest statement
Competing interests: None.
Similar articles
-
[Fever in patients with cancer].Rinsho Byori. 2009 May;Suppl 143:112-5. Rinsho Byori. 2009. PMID: 20845880 Review. Japanese. No abstract available.
-
An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile and neutropenic cancer patients.Eur J Cancer. 1995 Nov;31A(12):2013-22. doi: 10.1016/0959-8049(95)00292-8. Eur J Cancer. 1995. PMID: 8562158 Review.
-
Improving the immediate management of neutropenic sepsis in the UK: lessons from a national audit.Br J Haematol. 2011 Jun;153(6):773-9. doi: 10.1111/j.1365-2141.2011.08693.x. Epub 2011 Apr 22. Br J Haematol. 2011. PMID: 21517822 Review.
-
Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group.Pediatr Blood Cancer. 2005 Sep;45(3):274-80. doi: 10.1002/pbc.20366. Pediatr Blood Cancer. 2005. PMID: 15806544 Clinical Trial.
-
Variation in Management of Fever and Neutropenia Among Pediatric Patients With Cancer: A Survey of Providers in Michigan.Pediatr Hematol Oncol. 2015;32(5):331-40. doi: 10.3109/08880018.2015.1036331. Epub 2015 Jun 18. Pediatr Hematol Oncol. 2015. PMID: 26086779 Free PMC article.
Cited by
-
Updated systematic review and meta-analysis of the performance of risk prediction rules in children and young people with febrile neutropenia.PLoS One. 2012;7(5):e38300. doi: 10.1371/journal.pone.0038300. Epub 2012 May 31. PLoS One. 2012. PMID: 22693615 Free PMC article.
-
Developing a national 'low risk' febrile neutropenia framework for use in children and young people's cancer care.Support Care Cancer. 2013 May;21(5):1241-51. doi: 10.1007/s00520-012-1653-y. Epub 2012 Dec 20. Support Care Cancer. 2013. PMID: 23262805
-
Febrile neutropenia in children with cancer.Adv Exp Med Biol. 2009;634:185-204. doi: 10.1007/978-0-387-79838-7_16. Adv Exp Med Biol. 2009. PMID: 19280859 Free PMC article. Review.
-
A Dynamic Approach for Early Risk Prediction of Gram-Negative Bloodstream Infection and Systemic Inflammatory Response Syndrome in Febrile Pediatric Hemato-Oncology Patients.Children (Basel). 2022 Jun 3;9(6):833. doi: 10.3390/children9060833. Children (Basel). 2022. PMID: 35740770 Free PMC article.
-
Predicting microbiologically defined infection in febrile neutropenic episodes in children: global individual participant data multivariable meta-analysis.Br J Cancer. 2016 Mar 15;114(6):623-30. doi: 10.1038/bjc.2016.28. Epub 2016 Mar 8. Br J Cancer. 2016. PMID: 26954719 Free PMC article.
References
-
- Orudjev E, Lange B J. Evolving concepts of management of febrile neutropenia in children with cancer. Med Pediatr Oncol 200239(2)77–85. - PubMed
-
- Hann I, Viscoli C, Paesmans M.et al A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Br J Haematol 199799(3)580–588. - PubMed
-
- Viscoli C, EORTC International Antimicrobial Therapy Group Management of infection in cancer patients. Studies of the EORTC International Antimicrobial Therapy Group (IATG). Eur J Cancer 200238(Suppl 4)S82–S87. - PubMed
-
- National Institute of Clinical Excellence ( N I C E )Guidance on cancer services: improving outcomes in child and adolescent cancer. London: The Stationery Office, 2003
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical